Anna, a 42-year-old Swedish woman diagnosed with ALS in 2023, now faces a cautious but hopeful turn after Sweden’s National Board of Health and Welfare (Socialstyrelsen) reversed its stance on Qalsody, the first FDA-approved ALS treatment. The drug, which costs roughly $158,000 per year in the U.S., has just been approved for use in Sweden—marking a pivotal shift for patients like Anna, who had been excluded from access since the board initially denied coverage in 2024. “This is a lifeline, but we’re still waiting to see how the system will handle it,” Anna told Sveriges Radio in an interview this week, her voice steady despite the emotional weight of the news.
What makes this reversal even more significant is the speed: just six months after the board’s denial, a new committee within the National Board has recommended that select ALS patients—those with the hereditary form of the disease—be granted access to Qalsody. The decision hinges on a reassessment by the National Board’s drug committee, which cited emerging data showing the drug’s efficacy in slowing disease progression by up to 25% in clinical trials. Yet, the approval is not universal: only patients with a confirmed genetic mutation linked to ALS qualify, leaving others in limbo.
Why Sweden’s U-Turn on Qalsody Matters—And What It Means for Patients
The reversal is a rare victory for Sweden’s ALS community, which has long criticized the National Board’s rigid stance on experimental treatments. In 2024, the board denied coverage for Qalsody, arguing the evidence was insufficient—a decision that left patients like Anna without options. Now, the board’s about-face raises critical questions: How did this happen? And what does it say about Sweden’s approach to rare diseases?
According to Läkartidningen, the shift stems from pressure on two fronts. First, international data: The U.S. FDA approved Qalsody in 2022 after trials showed it extended survival by an average of 2.7 months in late-stage ALS patients. Second, patient advocacy: Organizations like the Swedish ALS Association (ALS Föreningen) mounted a campaign, collecting over 10,000 signatures demanding access. “We’ve been fighting for this for years,” said Erik Lindberg, the association’s CEO, in a statement. “This isn’t just about one drug—it’s about proving that the system can adapt when lives are on the line.”
Yet the approval is far from seamless. Qalsody’s cost—equivalent to roughly 10% of Sweden’s per-capita healthcare budget—has sparked debates about sustainability. The National Board’s committee acknowledged this in its recommendation, stating that “resource allocation must be carefully balanced against the drug’s proven benefits”. For now, only patients with the SOD1 gene mutation, which accounts for about 2% of ALS cases, qualify. Others, like Anna, must wait for further reviews.
Who Wins—and Who Loses—in Sweden’s ALS Treatment Policy Shift?
The new policy creates a two-tier system within Sweden’s ALS community. Patients with hereditary ALS now have a treatment option, but those with sporadic ALS—who make up the majority of cases—remain excluded. This disparity mirrors a broader trend in Europe, where access to cutting-edge drugs often depends on genetic factors rather than disease severity.
“The genetic distinction is a technicality that obscures the reality: ALS is a progressive killer, and time is the only resource we don’t have enough of. If Qalsody works for some, why not others?”
Dr. Westerlund, who has treated ALS patients for over a decade, points to a critical gap in Sweden’s healthcare framework: the lack of a unified ALS treatment strategy. While other countries, like the U.S. and UK, have fast-tracked ALS drug approvals under emergency designations, Sweden’s system remains fragmented. “We’re playing catch-up,” Westerlund says. “The question is whether this reversal will accelerate broader reforms—or if it’s just a temporary fix.”
The $158,000 Question: Can Sweden Afford to Treat ALS?
Cost is the elephant in the room. Qalsody’s price tag—set by its manufacturer, Biogen—has drawn comparisons to Sweden’s €1.2 billion annual budget for rare diseases. The National Board’s committee justified the approval by citing cost-effectiveness models, but critics argue the data is still preliminary. “We don’t yet know if the long-term benefits outweigh the costs,” said Dr. Lars Eriksson, an economist at Stockholm School of Economics, in an interview with Dagens Industri. “What we do know is that Sweden’s healthcare system is already strained. Adding a drug like this without a clear plan for sustainability risks crowding out other essential treatments.”
Yet for patients like Niklas Johansson, 58, who was diagnosed with ALS in 2025, the reversal is nothing short of a miracle. “I was told I had months left. Now, I have hope,” Johansson told Sveriges Radio after starting Qalsody in May. His story underscores the human cost of delay: ALS progresses rapidly, with patients losing mobility within 2–5 years of diagnosis. The average survival rate post-diagnosis is just 3–5 years, according to the World Health Organization. For hereditary ALS patients, Qalsody may buy them critical extra months—or even years.
What Happens Next? The Bureaucratic Hurdles Ahead
The National Board’s decision is not the final word. Regional health authorities, like Region Norrbotten, must now approve Qalsody for local use—a process that could take weeks to months. Meanwhile, the Swedish government is under pressure to clarify how it will fund the drug long-term. “This is a test case,” said Anna-Karin Hatt, a health policy analyst at the Swedish Association of Local Authorities. “If Qalsody proves effective, other regions will demand access. The system isn’t ready for this scale.”
Adding to the complexity is the lack of a national ALS registry in Sweden. Unlike countries such as the U.S., which maintains a comprehensive ALS database, Sweden relies on fragmented records, making it difficult to track patient outcomes or adjust policies in real time. “We’re flying blind,” Hatt warns. “Without data, we can’t measure success—or failure.”
A Cautious Hope—and a Call to Action
For Anna, the news is a glimmer of light in a long, dark tunnel. But her cautious optimism reflects a broader truth: Sweden’s healthcare system is at a crossroads. The Qalsody reversal is a victory for patients, but it also exposes systemic flaws in how Sweden handles rare and rapidly progressive diseases. The question now is whether this moment will spark meaningful change—or if it will be just another chapter in a story of delayed access.
One thing is clear: Time is running out. For ALS patients, every week without treatment is a week lost. As Anna puts it, “We don’t have the luxury of waiting for perfection. We need solutions—now.” The ball is in the government’s court. Will Sweden rise to the challenge?
